“Readying this type of breakthrough medical science for commercialization is just the type of advanced project and company that we look to support as part of Mentor’s $125 Million Direct Cancer Equity Funding Program.”
Mentor Capital CEO, Chester Billingsley, explains the advantage over Gamma Knife or even the latest in Proton Radiology. “Neutrons pass harmlessly through human tissue without the collateral damage of radiation. However, if just a few atoms of Gadolinium – 157 are biologically tagged within the cancer nuclei, the extremely large neutron cross-section of this stable isotope will result in the absorption of a neutron adjacent to a cancerous DNA string. Immediately, a highly energetic electron is ejected with sufficient energy to cleave the double DNA strand, stopping the cancer cell.” He continues, “Readying this type of breakthrough medical science for commercialization is just the type of advanced project and company that we look to support as part of Mentor’s $125 Million Direct Cancer Equity Funding Program.”
Importantly, the Hadron system is classified as a medical device, and a clinical trial to include late-stage cancer patients is planned for September 2012. Hadron Systems; Technology Coordinator; F.W. Fischer will be responsible for applying $5 Million toward this last stage of product test: "Particle therapy is universally recognized to be curative for patients diagnosed with cancer at an early stage. Biologically guided particle therapy is the next plateau in radiotherapy, damaging the tumor microenvironment, whether of the primary tumor, cancer infiltration of the lymph system, small tumors or metastases of host organs. In doing so, the effect is immune recognition and a strong immune response to tumors."
Mentor Capital securities structure is 93% warrants with only 2 million shares outstanding. As a result, asset accumulation, such as with this $5 Million of Hadron shares, will strongly influence the early exercise of some of Mentor’s $125 Million in warrants that are earmarked to be paid out to Hadron and others. In this manner, the associated new and existing shareholder purchases are focused along the lines of the socially responsible investment and cancer benefits that Mentor Capital shareholders have requested.
A sample of a $10 Million pro forma Direct Cancer Equity Contract, similar to the contract with Hadron, with additional relevant information, is presented at www.MentorCapital.com.
Forward Looking Statements, Safe Harbor and Risk Descriptions are Incorporated by Reference from the MNTR Company Web Site above.
Contacts
Mentor Capital, Inc. Chester Billingsley, CEO 760-788-4700
